Cargando…
Inhibition of androgen receptor enhanced the anticancer effects of everolimus through targeting glucose transporter 12
Everolimus was designed as a mammalian target of rapamycin (mTOR) inhibitor. It has been proven as a targeted drug for gastric cancer (GC) therapy. However, long-term treatment with everolimus may cause severe side effects for recipients. Decreasing the dosage and attenuating the associated risks ar...
Autores principales: | Cao, Bo, Zhao, Ruiyang, Li, Hanghang, Xu, Xingming, Gao, Jingwang, Chen, Lin, Wei, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760431/ https://www.ncbi.nlm.nih.gov/pubmed/36594084 http://dx.doi.org/10.7150/ijbs.75106 |
Ejemplares similares
-
Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation
por: Cao, Bo, et al.
Publicado: (2021) -
circDNMT1 Promotes Malignant Progression of Gastric Cancer Through Targeting miR-576-3p/Hypoxia Inducible Factor-1 Alpha Axis
por: Li, Hanghang, et al.
Publicado: (2022) -
Critical Signaling Transduction Pathways and Intestinal Barrier: Implications for Pathophysiology and Therapeutics
por: Gao, Jingwang, et al.
Publicado: (2023) -
Glucose starvation suppresses gastric cancer through targeting miR-216a-5p/Farnesyl-Diphosphate Farnesyltransferase 1 axis
por: Zhao, Ruiyang, et al.
Publicado: (2021) -
LOW-INTENSITY EXERCISE ENHANCES MUSCULAR ANDROGEN/ANDROGEN RECEPTOR TO INHIBIT MYOSTATIN PATHWAY
por: Son, Bo-Kyung, et al.
Publicado: (2019)